Clinical Support

CKD progression

Studies of plasma biomarkers for CKD progression

READ STUDIES

KidneyIntelX

Studies supporting utility and impact of KidneyIntelX

READ STUDIES

FractalDx

Studies supporting utility and impact of FractalDx

READ STUDIES
03Aug

KidneyIntelX in Multi-Center Study to Monitor and Predict Kidney Risk in COVID-19 Patients

Surge in Chronic Kidney Disease and Kidney Failure Expected Post-COVID-19 Mount Sinai-Led Study to Assess 4,000 Surviving COVID-19 Patients.. Read More →
31Jul

Total Voting Rights

As of 31 July 2020, the Company's issued and fully paid share capital consists of 72,029,634 ordinary shares with a nominal value of £0.0025 each,.. Read More →

Join our
Investor Newsletter

Loading